Candida sepsis from local infection in a patient with a urostomy on SGLT2 inhibitor therapy. (September 2020)

• Record Type: Journal Article
• Authors: Wendt, Ralph; Schmerler, Diana; Müller-Hechler, Charlotte; Weichold, Christian; Craatz, Diana; Beige, Joachim
• Is Part Of: International journal of infectious diseases. Volume 98(2020)
• Page Start: 227
• Page End: 229
• Publication Date: 2020-09
• Subjects: SGLT2 inhibitors -- SGLT2i, Candida glabrata -- Urostomy; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2020.06.073
• Languages: English
• ISSNs: 1201-9712

Abstract

Abstract: Sodium–glucose co-transporter 2 (SGLT2) inhibitors exhibit impressive cardio-renal benefits in patients with a high cardiovascular risk. Genital yeast infections are important side effects of this class of drugs. We report a case of Candida glabrata sepsis secondary to a Candida infection of the urostomy of a patient on SGLT2 inhibitor therapy. In urostomy patients, one should critically evaluate the risk of mycotic infections against the cardiovascular and glycaemic benefits of SGLT2 inhibition. Urostomy patients without a high cardiovascular risk should not be treated with SGLT2 inhibitors.